The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03085485|
Recruitment Status : Recruiting
First Posted : March 21, 2017
Last Update Posted : August 21, 2018
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease Chronic Bronchitis||Drug: Ivacaftor 150 MG Drug: Placebo||Phase 2|
Like CF, COPD is characterized by small airway mucus obstruction that is associated with accelerated loss of lung function and mortality. Preliminary data indicate that cigarette smoke exerts deleterious effects on airway epithelial function including the reduction of CFTR activity, enhanced mucus expression, and a pronounced reduction in mucociliary transport (MCT). Preliminary data also indicate that approximately 50% of patients with COPD have reduced CFTR activity, as detected in the upper airways, lower airways and sweat glands. Furthermore, CFTR dysfunction is independently associated with chronic bronchitis, can persist despite smoking cessation, and can be reversed by the CFTR potentiator ivacaftor (VX-770) in vitro by activating wild-type CFTR, resulting in a robust increase in MCT. Combined with unprecedented clinical improvement via augmented mucociliary clearance in CF patients with a responsive CFTR mutation treated with ivacaftor, these data indicate that CFTR represents a viable therapeutic target to address mucus stasis in a large subset of COPD patients (potentially representing over 4 million patients in the U.S. alone). This project will investigate the hypothesis that ivacaftor can augment CFTR activity in individuals with COPD who exhibit chronic bronchitis, resulting in meaningful improvements in epithelial function and respiratory health. The investigators' initial pilot study in patients with COPD and chronic bronchitis demonstrated that ivacaftor was safe, demonstrated stable pharmacokinetics, and exhibited a trend towards efficacy in measures of PROs and sweat chloride. The current trial will test the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in a larger number of COPD patients with chronic bronchitis and for a longer treatment period, evaluating the potential of CFTR potentiator therapy to address acquired CFTR dysfunction in this population and set the stage for larger and longer-term trials in the future. Based on an IND already in place in the Rowe laboratory, an IRB familiar with the proposed study, an experienced clinical investigation team with expertise in all of the endpoints proposed, and a well characterized COPD population prioritized for the presence chronic bronchitis, CFTR dysfunction, and the absence of congenital CFTR mutations, the investigators are poised to deliver the trial.
Enrollment is planned at a single center, The University of Alabama at Birmingham. Patients will be randomized 3:1 to active drug (n=30) and placebo (10) to achieve the enrollment goal.
A sufficient number of subjects will be screened to randomize up to 50 subjects to achieve 40 completed subjects to receive either ivacaftor 150 mg BID (n=30) or placebo (n=10) for 84 days.
Ivacaftor and matching placebo will be orally administered as capsules according to the following guidelines:
Between study visit Day 1 and study visit Day 84, subjects will take 1 dose of study drug each day in the morning, beginning any time between 08:00 h (8:00 AM) and 12:00 h (12:00 PM). Whenever possible, subjects should take the study drug at the same time each day.
On the study visit days when PK samples are collected (study visit Days 1, 28, 56, and 84), the study drug is to be taken by the subject while he/she is at the study site
For visits after the Day 1 visit, subjects will be instructed to bring all remaining study drug materials to the site; study drug will be dispensed at each visit.
Ivacaftor will be prepared and dispensed by an unblinded pharmacist.
Subjects will be instructed to continue their standard COPD medication regimen.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||The design is a pilot, randomized (3:1, active:placebo), double-blind, placebo-controlled study|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The Topic Trial)|
|Actual Study Start Date :||March 16, 2017|
|Estimated Primary Completion Date :||April 2019|
|Estimated Study Completion Date :||April 2019|
Active Comparator: Ivacaftor
Ivacaftor, 150 mg PO every 12 hrs for 84 days
Drug: Ivacaftor 150 MG
Ivacaftor is a CFTR potentiator
Other Name: KALYDECO
Placebo Comparator: Placebo
- Safety of ivacaftor - number of participants with adverse events [ Time Frame: From Screening to Day 98 ]Safety of ivacaftor will be determined by number of participants with adverse events (including serious adverse events).
- Safety of ivacaftor - number of participants with abnormal serum chemistry [ Time Frame: From Screening to Day 98 ]Number of participants with abnormal serum chemistry values compared to screening values will also be used to determine safety of ivacaftor.
- Safety of ivacaftor - number of participants with abnormal hematology [ Time Frame: From Screening to Day 98 ]Safety of ivacaftor will also be determined by number of participants with abnormal changes in their screening hematology values.
- Safety of ivacaftor - number of participants with abnormal ECG [ Time Frame: From Screening to Day 98 ]Number of participants with abnormal changes in their screening ECGs is another factor that will be used to evaluate the safety of ivacaftor.
- Central CFTR activity measured by Mucociliary Clearance (MCC) [ Time Frame: From Screening to Day 98 ]Clearance of Tc99 sulfur colloid is a measure of MCC of the lungs, and is calculated by a standard protocol developed by the Cystic Fibrosis Therapeutics Development Network. The method provides a robust measure of MCC, and has been sensitive to the effects of inhaled pharmacologic agents in CF and COPD including improvements of an unprecedentedly large magnitude in CF patients with the G551D-CFTR mutation treated with ivacaftor measured in a multicenter study. The technique allows estimates of MCC in both the small and large airway compartments.
- Peripheral CFTR activity measured by Sweat Chloride [ Time Frame: From Screening to Day 98 ]Sweat chloride abnormality is correlated with COPD severity and symptoms, and is a highly sensitive outcome measure for CFTR-directed therapeutics. We have shown sweat chloride is sensitive to the presence of cigarette smoking and COPD, and the test has been successfully used as an endpoint in multiple CF trials, including studies to detect the efficacy of ivacaftor therapy.
- Indicators of respiratory function and COPD health : Change in FEV1 [ Time Frame: From Screening to Day 98 ]Spirometry is a standard outcome measure in COPD and a major indicator of efficacy and safety in COPD clinical trials. Post-bronchodilator spirometry will be performed by ATS criteria. FEV1 will be measured in liters (L).
- Indicators of respiratory function and COPD health : Change in FVC. [ Time Frame: From Screening to Day 98 ]Spirometry is a standard outcome measure in COPD and a major indicator of efficacy and safety in COPD clinical trials. Post-bronchodilator spirometry will be performed by ATS criteria. FVC will be measured in liters (L).
- San Diego Shortness of Breath Questionnaire (SOBQ) [ Time Frame: From Screening to Day 98 ]The SOBQ is a self-reported questionnaire that assesses shortness of breath while performing a variety of activities of daily living. The Minimum Clinically Important Difference (MCID) is 5.
- Breathlessness, Cough, and Sputum Scale (BCSS) [ Time Frame: From Screening to Day 98 ]The BCSS is a three-item questionnaire rating breathlessness, cough and sputum on a 5-point Likert scale from 0 (no symptoms) to 4 (severe symptoms).
- COPD Assessment Test (CAT) [ Time Frame: From Screening to Day 98 ]CAT is a self reported questionnaire that measures COPD related quality of life. The MCID is 2.
- St. George Respiratory Questionnaire (SGRQ) [ Time Frame: From Screening to Day 98 ]The SGRQ is a disease-specific measure of health status for use in COPD with an MCID of 4.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03085485
|Contact: Mark T Dransfield, MDfirstname.lastname@example.org|
|United States, Alabama|
|UAB Lung Health Center||Recruiting|
|Birmingham, Alabama, United States, 35294|
|Contact: Mark T Dransfield, MD 205-934-5555|
|Principal Investigator: Mark T Dransfield, MD|